IDH1 and acute myeloid leukemia: Based on their better efficacies with the consideration of less toxicity, IDH inhibitors are being used for specific patients, based on their biological phenotype regarding white blood cells and the patients’ response to the previously approved drugs, with a strong commitment to seek the best outcomes for patients of AML.